Download this White Paper to Learn More
Live Biotherapeutics (LBPs) are no longer just a scientific curiosity, they are becoming one of the most promising frontiers in modern medicine.
By harnessing live microorganisms to restore or modulate human health, LBPs are opening new pathways for treating chronic and complex diseases with precision and minimal toxicity. From gastrointestinal and metabolic disorders to neurodegeneration and oncology, LBPs have the potential to fundamentally reshape how we approach drug development.
As interest in LBPs accelerates, Novotech’s white paper outlines the opportunities and early-stage challenges shaping this rapidly advancing therapeutic class.
The FDA’s approval of Rebyota™ and Vowst™ has validated the category, but most programs remain in early development. According to Novotech’s analysis:
- More than 90 industry-sponsored trials have launched since 2020, but 32% have been withdrawn or suspended due to regulatory, manufacturing, or trial design complexity
- Preclinical and early-phase LBP programs are increasingly targeting Alzheimer’s, IBD, diabetes, and NASH
- North America and Europe lead in regulatory and CDMO investment, but Asia-Pacific is gaining momentum
- The global market for microbiome CDMO services is projected to grow at a CAGR of 38% through 2030
With investment growing and competition intensifying, the next wave of success will require biotech sponsors to master clinical feasibility, regulatory navigation, and smart trial design from the earliest stages.
Download the white paper
Offered Free by: Novotech
See All Resources from: Novotech
